irinotecan sucrosofate: Clinical Trials

105 trials of irinotecan sucrosofate, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 recruiting, 20 not yet recruiting, 19 completed, 17 unknown. 105 Phase 2, 19 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2105Recruiting 30, Not yet recruiting 20, Completed 19, Unknown 17, Active not recruiting 9, Withdrawn 5, Terminated 4, Enrolling by invitation 1
Phase 119Recruiting 5, Not yet recruiting 4, Unknown 3, Withdrawn 3, Active not recruiting 1, Completed 1, Enrolling by invitation 1, Terminated 1
Phase 32Not yet recruiting 1, Withdrawn 1

Follow irinotecan sucrosofate: new trials by email Literature Review of irinotecan sucrosofate trials Research Report on irinotecan sucrosofate

Trials (filtered) newest first · largest first

All 105 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors
Zanidatamab - Biliary Tract Cancer
Phase 2Not yet recruitingAnhui Provincial Hospital152026-11-302026-10-01
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
Liposomal Irinotecan, Oxaliplatin, Capecitabine - Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital282026-05-302026-05-06
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital302026-05-302026-05-18
Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer
Short-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine - Rectal Cancer Patients
Phase 2Not yet recruitingGuangdong Provincial People's Hospital442026-05-202026-04-13
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab - Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan
Phase 2 / Phase 3Not yet recruitingHebei Medical University Fourth Hospital4082026-05-202026-05-13
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil - Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Phase 2RecruitingMedical University of South Carolina522026-04-022026-05-06
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Liposomal Irinotecan, Apatinib in arm1 - Osteosarcoma, Osteosarcoma Metastatic
Phase 1 / Phase 2RecruitingPeking University People's Hospital562026-03-052026-03-18
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Biospecimen Collection, Computed Tomography, Fluorouracil - Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase 2RecruitingRoswell Park Cancer Institute202026-03-022026-09-21
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib - Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital332026-03-012026-03-03
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors - Intrahepatic Cholangiocarcinoma (Icc)
Phase 2Active not recruitingTianjin Medical University Cancer Institute and Hospital302026-02-242026-06-15
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab - Malignant Ascites
Phase 1 / Phase 2RecruitingDong sheng Zhang482025-11-282026-02-09
Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer
Irinotecan Liposome, Capecitabine, and Enlansubemab Plus Short-Course Radiotherapy - Advanced Rectal Cancer
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital302025-11-012026-06-03
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
Bevacizumab,Irinotecan liposome (II),5-FU/LV - Colorectal Cancer
Phase 2Not yet recruitingSanjun Cai3002025-09-012025-08-14
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
Irinotecan Liposomal - Gastric Cancer
Phase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou University332025-08-152025-07-31
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
nanoliposomal irinotecan plus carboplatin - GEP-NET
Phase 1 / Phase 2Enrolling by invitationNational Health Research Institutes, Taiwan522025-08-142025-08-15
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
Nal-IRI, Ciprofloxacin, Paclitaxel - PDAC - Pancreatic Ductal Adenocarcinoma
Phase 2Not yet recruitingGERCOR - Multidisciplinary Oncology Cooperative Group2062025-07-012025-07-01
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil - Small Bowel Adenocarcinoma
Phase 2RecruitingTiago Biachi de Castria362025-06-302026-07-28
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
NALIRIFOX, Gemcitabine plus nab-Paclitaxel (GnP) - Pancreatic Ductal Adenocarcinoma
Phase 2RecruitingNorthwell Health412025-06-262026-09-25
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Ivonescimab, Nimotuzumab, Irinotecan liposome - Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2RecruitingMing-Yuan Chen2082025-06-242025-09-18
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Adebelizumab combined with irinotecan liposome as second-line therapy - Small Cell Lung Cancer
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute462025-06-012025-06-08

Showing 20 of 105. Sign in to see all of them.

Conditions studied

Pancreatic Neoplasms (21)  ·  Colorectal Neoplasms (14)  ·  Biliary Tract Neoplasms (5)  ·  Small Cell Lung Carcinoma (5)  ·  Neoplasm Metastasis (4)  ·  Stomach Neoplasms (4)  ·  Cholangiocarcinoma (3)  ·  Neoplasms (3)  ·  Osteosarcoma (3)  ·  Recurrence (3)  ·  Rhabdomyosarcoma (3)  ·  Sarcoma, Ewing (3)  ·  Fallopian Tube Neoplasms (2)  ·  Gastrointestinal Neoplasms (2)  ·  Nasopharyngeal Carcinoma (2)

Sponsors

Tianjin Medical University Cancer Institute and Hospital (6)  ·  CSPC Ouyi Pharmaceutical Co., Ltd. (3)  ·  Hebei Medical University Fourth Hospital (3)  ·  National Health Research Institutes, Taiwan (3)  ·  Sun Yat-sen University (3)  ·  The First Affiliated Hospital with Nanjing Medical University (3)  ·  West China Hospital (3)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)  ·  Federation Francophone de Cancerologie Digestive (2)  ·  Fudan University (2)  ·  Harbin Medical University (2)  ·  Institut de Recherches Internationales Servier (2)  ·  Roswell Park Cancer Institute (2)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (2)

Countries

China (39)  ·  United States (28)  ·  Spain (6)  ·  Taiwan (6)  ·  South Korea (5)  ·  Germany (4)  ·  Japan (4)  ·  Canada (3)  ·  France (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Belgium (1)  ·  Denmark (1)

Top investigators

Abi Vainstein, MD (1)  ·  Afsaneh Barzi, MD (1)  ·  Albert Lockhart, MD (1)  ·  Alberto Pappo, MD (1)  ·  Antonio Cubillo, MD (1)  ·  Arndt Vogel, Prof. (1)  ·  Ashley Frith, M.D. (1)  ·  Baorui Baorui Liu, Doctor (1)  ·  Benjamin Weinberg, MD (1)  ·  Changhoon Yoo (1)  ·  Chengzhi Zhou, Doctor (1)  ·  Christos Fountzilas (1)  ·  Daniela E Matei, M.D. (1)

Results publications

PMID 40147791, PMID 11230497, PMID 11489791, PMID 11895891, PMID 16271446, PMID 1651156, PMID 17468871, PMID 19349540, PMID 22811849, PMID 23406728, PMID 23880820, PMID 25577133, PMID 26615328, PMID 27091418, PMID 27871319, PMID 30525443, PMID 32029495, PMID 32451495, PMID 33284237, PMID 33403007, PMID 33835977, PMID 33957442, PMID 34656226, PMID 34750990, PMID 36951834, PMID 36963200, PMID 37056765, PMID 37287870, PMID 37753702, PMID 38870977, PMID 39492841, PMID 39701097, PMID 39987459, PMID 40468090, PMID 40876084, PMID 41117518, PMID 41921365, PMID 42256682, PMID 42371783

NIH funding

2016 (2), 2017 (2), 2015 (1), 2019 (1), P30CA014089 (1), P30CA015083 (1), P30CA060553 (1), U10CA180820 (1)